固体瘤中的双特异性抗体:进步和挑战
Khine Swe Shan1, Saba Musleh Ud Din2, Shivani Dalal1
1Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33028, USA.
International journal of molecular sciences
|June 26, 2025
概括
双特异性抗体 (BsAbs) 通过向两个抗原,提供了新的癌症免疫疗法选择. 虽然在血液癌症中取得了成功,但BsAbs现在在固体瘤中表现有前途,有几种已获得批准,更多正在开发中.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 双特异性抗体 (BsAbs) 是人工合成的蛋白质,可以结合两个不同的抗原,从而在癌症免疫疗法中实现新的治疗机制.
- 虽然BsAbs在血液性恶性瘤中取得了成功,但它们在固体瘤中的应用面临挑战,但正在迅速发展.
研究的目的:
- 审查BsAbs在癌症治疗中的作用机制.
- 提供目前已批准和正在开发的BsAbs用于固体瘤的概述.
- 讨论挑战,毒性管理和BsAbs在固体瘤治疗中的未来方向.
主要方法:
- 对双特异性抗体机制,已批准的疗法和正在进行的临床试验的文献综述.
- 对BsAbs在固体瘤中的监管批准 (FDA和中国) 的分析.
- 综合关于临床发展,挑战和未来前景的信息.
主要成果:
- 五种BsAbs (amivantamab,tarlatamab,tebentafusp,zanidatamab,zenocutuzumab) 被FDA批准用于固体瘤;两个 (cadonilimab,ivonescimab) 在中国被批准.
- 许多BsAbs正处于固体瘤的早期临床开发阶段,这表明正在进行重要的研究.
- 临床使用和毒性管理方面的挑战是BsAb治疗的关键考虑因素.
结论:
- BsAbs代表了癌症免疫治疗的重大进步,在固体瘤中效率越来越高.
- 持续的研究和开发对于克服挑战和扩大BSAbs的治疗潜力至关重要.
- 未来的方向侧重于优化BsAb设计,临床应用和对固体恶性瘤的患者管理.
相关概念视频
Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Vaccines
520
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
520
Hybridoma Technology
15.4K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.4K


